Moderna (MRNA)
(Delayed Data from NSDQ)
$118.19 USD
-3.06 (-2.52%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $118.58 +0.39 (0.33%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Moderna, Inc. [MRNA]
Reports for Purchase
Showing records 201 - 220 ( 260 total )
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Coronavirus Vol. 38: MRNA Vaults to the Head of the Pack for COVID Testing
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Coronavirus Vol. 30: BARDA Award Provides Lift-off for Moderna''s COVID Vaccine
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Coronavirus Vol. 29: Four Wins on the COVID-19 Front
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
BARDA Award Puts the Spotlight on mRNA-1273 Against COVID-19
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Coronavirus Vol. 27: COVID''s Origin in Bats and a Nuanced Weakness of the Virus
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - Coronavirus Vol. 17: U.S. at ~100k Tests Per Day and Why Antibody Assays Matter
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare- Yas'' Weekly Recap of Our Key Notes and 20 Doc Calls Upcoming in 2Q20
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Dial in to Part 2 of Our COVID-19 Drug Developer Call Series Today at 12PM
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare Coronavirus Vol. 16: Newly Updated ClinicalTrials.gov Tracker
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare Dial in to Part 1 of Our COVID-19 Drug Developer Call Series Today at 12PM
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - Dial in to Parts 1-2 of Our COVID-19 Drug Developer Series on Apr. 1 - Apr. 2
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Impact from COVID-19 Puts Even More Focus on Vaccines
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Moderna, Inc.
Industry: Medical - Biomedical and Genetics
Market Shudders But We See Names to Outperform.
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department